The Attractiveness of Investing In Haemonetics Corporation (HAE) is Growing

0
13

In a filing, Haemonetics Corporation revealed its President, Global Hospital Strong Stewart W unloaded Company’s shares for reported $6029.0 on Oct 24. In the deal valued at $80.39 per share,75 shares were sold. As a result of this transaction, Strong Stewart W now holds 15,681 shares worth roughly $ 1.31 million.


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.

Sponsored


Then, Basil Michelle L sold 180 shares, generating $14,470 in total proceeds. Upon selling the shares at $80.39, the EVP and General Counsel now owns 32,455 shares.

Before that, Miller Laurie A. sold 212 shares. Haemonetics Corporation shares valued at $16,165 were divested by the SVP, Human Resources at a price of $76.25 per share. As a result of the transaction, Miller Laurie A. now holds 12,697 shares, worth roughly $1.06 million.

Mizuho initiated its Haemonetics Corporation [HAE] rating to a Buy in a research note published on Monday, October 13, 2022; the price target was $90. PT values the company’s stock at a premium of 7.14 to its Monday closing price. A number of analysts have revised their coverage, including Needham’s analysts, who decreased its forecast for the stock in late January from “a Buy” to “a Hold”. Citigroup also remained covering HAE and has decreased its forecast on December 15, 2021 with a “Neutral” recommendation from previously “Buy” rating.

Price Performance Review of HAE

On Monday, Haemonetics Corporation [NYSE:HAE] saw its stock jump 3.61% to $83.57. On the same session, the stock had its day’s lowest price of $81.80, but rose to a high of $85.61. Over the last five days, the stock has lost -1.62%. Haemonetics Corporation shares have risen nearly 57.56% since the year began. Nevertheless, the stocks have risen 12.04% over the past one year. While a 52-week high of $85.97 was reached on 11/01/22, a 52-week low of $43.50 was recorded on 01/28/22. SMA at 50 days reached $77.34, while 200 days put it at $64.83. A total of 0.7 million shares were traded, compared to the trading of 0.45 million shares in the previous session.

Levels Of Support And Resistance For HAE Stock

The 24-hour chart illustrates a support level at 81.71, which if violated will result in even more drops to 79.85. On the upside, there is a resistance level at 85.52. A further resistance level may holdings at 87.47. The Relative Strength Index (RSI) on the 14-day chart is 61.16, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.22, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bullish at 27.84%. Stochastics %K at 46.61% indicates the stock is a holding.

How much short interest is there in Haemonetics Corporation?

A steep rise in short interest was recorded in Haemonetics Corporation stocks on Jul 14, 2022, growing by 50000.0 shares to a total of 1.87 million shares. Yahoo Finance data shows the prior-month short interest on Jun 14, 2022 was 1.82 million shares. There was a rise of 2.67%, which implies that there is a positive sentiment for the stock. In spite of short shares comprising just 5.61% of the overall stock float, the days-to-cover ratio (short ratio) rose to 3.91.

Haemonetics Corporation [HAE] – Who Are The Largest Shareholders?

In filings from Capital Research & Management Co, it is revealed that the company now owns 6,281,436 shares, or roughly 12.24% of the outstanding HAE shares. In other words, the investor’s shares have risen by 829,430 from its previous 13-F filing of 5452006.0. Additionally, Wellington Management Co. LLP decreased -8.55% of its stake after which the total value it holdings stand at $417,387,359, while The Vanguard Group, Inc. added 6.22% of its stake to hold $384.6 million in the firm. Over the last quarter, BlackRock Fund Advisors sold -118,957 shares of Haemonetics Corporation, while Neuberger Berman Investment Advis sold -50,242 shares. At present, SSgA Funds Management, Inc. is holding 1,669,517 shares valued at $123.59 million. Franklin Advisers, Inc. owned 1,293,760 shares of the company at the time of its most recent 13F filing, worth $95.78 million.

According to FactSet, Haemonetics Corporation’s share price will average $87.29 in the next year, based on opinions of analysts polled by the firm. This is up nearly 9.1 percent from its previous closing price of $80.66. Analysts expect Haemonetics Corporation stock to reach the higher price of $90.00, while the lowest price estimate is $80.00. However, 8 analysts have rated HAE stock as an Overweight in their predictions for 2022. The most recent change occurred on June 17, 2021 when Citigroup began covering the stock and recommended ‘”a Buy”‘ rating along with a $75 price target.

LEAVE A REPLY

Please enter your comment!
Please enter your name here